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MYC sustains non-stop proliferation by altering metabolic machinery to support growth
of cell mass. As part of the metabolic transformation MYC promotes lipid, nucleotide
and protein synthesis by hijacking citric acid cycle to serve biosynthetic processes,
which simultaneously exhausts ATP production. This leads to the activation of cellular
energy sensing protein, AMP-activated protein kinase (AMPK). Cells with normal growth
control can stop cell proliferation machinery to replenish ATP reservoirs whereas
MYC prevents such break by blocking the cell cycle exit. The relentless cell cycle
activation, accompanied by sustained metabolic stress and AMPK activity, switches the
energy-saving AMPK to pro-apoptotic AMPK. The AMPK-involving metabolic side of
MYC apoptosis may provide novel avenues for therapeutic development. Here we first
review the role of anabolic MYC and catabolic AMPK pathways in context of cancer and
then discuss how the concomitant activity of both pathways in tumor cells may result in
targetable synthetic lethal vulnerabilities.
Keywords: MYC, AMPK, cancer metabolism, apoptosis, glycolysis, glutamine metabolism, anaplerosis, synthetic
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MYC–EXPLOITING VULNERABILITIES IN CANCER METABOLIC
PROGRAMS
The classical view of oncogenic MYC expression being a cell cycle reprogrammer has recently
broadened in the light of new genome-scale promoter and transcriptomic studies, which have
exposed MYC’s widespread transcriptional impact across the genome and especially on the genes
orchestrating anabolic metabolism (Eilers and Eisenman, 2008; Dang, 2012; Kress et al., 2015).
MYC not only directly stimulates the core cell cycle machinery, but also prepares the cells for cell
division by globally stimulating cell growth and acquisition of macromolecules so that the cells
can successfully progress through different cell cycle checkpoints to complete the mitotic cycle
(Dang, 2013; Kress et al., 2015). Unlike healthy cells, most tumor cells cannot switch off MYC
expression in response to anti-proliferative signals from outside of the cell. Hence, sustained high
level MYC expression establishes an irreversible metabolic transformation, which can operate as an
autonomous cell cycle machinery on its own right—via incessant generation of biomass for growth,
which then consequently pushes the cell cycle progression forward (Stine et al., 2015).
This increased understanding of MYC’s role in control of metabolic machinery has conceived
new ideas and concepts for rational design of therapeutic synthetic lethal strategies to treat cancer.
The “indirect” MYC targeting strategies are often based on the simple idea that MYC-transformed
cells, since unable to exit from the cell cycle, would be extremely vulnerable to treatment that
perturbs the cell growth supporting anabolic programs or limiting metabolites. Such disturbance in
enforced anabolic metabolism leads to metabolic stress and (re-)activation of cell cycle checkpoints
and consequently, selective induction of apoptosis in transformed cells (Stine et al., 2015). A
good example of targetable MYC-dependent metabolic alteration is the striking addiction of
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MYC-transformed cells to availability of glutamine-derived
carbon (see below). The metabolic alterations caused by
MYC also stimulate AMPK activity, which can unleash both
survival and apoptosis pathways (see below). While the context-
dependency parameters here are still poorly understood, it
is noteworthy that AMPK activity is targetable with safe
drugs traditionally used for treatment of metabolic disorders.
Therefore, uncovering the secrets of the pro-apoptotic AMPK
function is likely to be a highly rewarding task with ample
of repurpose-able drug candidates available for proof-of-
mechanism testing.
Solid demonstration of the clinical feasibility of any MYC-
based synthetic lethal strategy still awaits to come forth but it is
important to note that at general level, the concept of attacking
cancer metabolic vulnerabilities has been fully validated in the
clinic. For example, treatment of cancer with chemotherapy
agent fluorouracil (5-FU), which is an inhibitor of thymidylate
synthase, or with methotrexate, an inhibitor of dihydrofolate
reductase and folates, leads to depletion of deoxyribonucleotides
and perturbed DNA synthesis, which amounts a lethal level
metabolic stress to cancer cells (Longley et al., 2003).
MYC–MASTER OF CELL CYCLE AND
GROWTH
MYC has wide variety of functions but one that stands out
in nearly all experimental systems and models is a positive
regulation of cell proliferation and growth. Already early
findings demonstrated MYC upregulation at cell cycle entry,
association of high MYC expression with proliferation active
embryonic and adult tissues, as well as revealed the ability
of an enforced MYC expression to induce growth factor-
independent cell cycle entry and prevent the cell cycle exit
(Eilers et al., 1991; Evan et al., 1992; Pelengaris et al., 2002).
These observations guided many early studies to specifically
focus on MYC’s role in transcriptional regulation of core cell
cycle and DNA replication related genes, as MYC logically
was pictured as a key driver of the cell cycle machinery.
MYC indeed directly regulates number of genes important for
the core cell cycle machinery. For example, MYC represses
the expression of CDK inhibitors p21CIP1, p15INK4B, and
p27KIP1 (reviewed in Kress et al., 2015) and transcriptionally
activates the genes of cyclin D and cyclin-dependent kinase
4 (Stine et al., 2015). MYC promotes the expression of
E2F transcription factors, which mediate progression into S
phase and the combined MYC and E2F activity induces DNA
replication genes to both initiate and sustain DNA replication
(Zeller et al., 2003, 2006; Dong et al., 2014). MYC also
transcriptionally regulatesmiRNA clustermiR-17-92 to attenuate
E2F1 functions in S-phase, which mechanism appears to be
important for keeping the rate of DNA replication in check
(Dominguez-Sola et al., 2007; Aguda et al., 2008). Notably,
MYC localizes to early sites of DNA replication and binds
many components of the pre-replicative complex, suggesting
transcription-independent regulatory functions in initiation of
DNA replication (Dominguez-Sola et al., 2007).
Recent unbiased genome-wide gene expression and
chromatin immunoprecipitation (ChIP) analyses combined with
next-generation sequencing have indeed corroborated earlier
findings by exposing plethora of MYC regulated genes with
annotated functions in cell cycle regulation and DNA replication
(Figure 1). However, the new data have also broadened earlier
views by demonstrating, first, that physiological (∼normal)
and supraphysiological (∼oncogenic) levels of MYC operate
partially via different gene-sets since only the supraphysiological
MYC binds and transcriptionally activates/represses genes
whose expression is directed by enhancer/promoter regions
with low affinity for MYC:MAX heterodimers; or, with low
affinity for transcription repressing complexes involving MYC
and for example, MIZ-1 (Walz et al., 2014; Wiese et al., 2015).
FIGURE 1 | Transcriptional domains of low and high level of MYC
expression. In the nucleus MYC binds together with MAX to
E-box-containing DNA sequences when they are accessible in chromatin,
occupying enhancer and promoter regions of thousands of genes. In humans,
MYC binds up to 10–15% of genomic loci (Eilers and Eisenman, 2008). The
supraphysiologically expressed (oncogenic) MYC targets virtually all active
promoters and enhancers in the genome, postulating a role for MYC at least in
these circumstances as a universal amplifier of expressed genes (Lin et al.,
2012; Nie et al., 2012). However, MYC binding does not always alter the
gene’s transcriptional activity (Dang, 2013). Furthermore, recent investigations
studying the impact of increasing MYC levels to global promoter occupancy
have suggested that elevated MYC levels have only minor effect on the MYC
binding to classical E-box high-affinity MYC promoters—possibly because
they are already employed by the physiological MYC (depicted as a blue circle
in the figure). Instead, the high MYC concentration predominantly and
indirectly leads to selective occupancy of sets of enhancers and promoters
with normally only weak affinity to MYC (Sabo et al., 2014; Walz et al., 2014;
Lorenzin et al., 2016) (depicted as a pink circle in the figure). Such promoter
“invasion,” which occurs in cells with high-level MYC expression, may lead to
activation or repression of novel pathways that are not influenced by the
normally regulated MYC (Wiese et al., 2015). Therefore, MYC may claim its
status as a major oncogene through qualitative attributes, including new
interaction patterns with companion transcription factors and off-target
promoter invasion on accessible sites in the chromatin, rather than only via
quantitative (general amplifier) functions (Horiuchi et al., 2012; Walz et al.,
2014). Examples of MYC-regulated genes in each category of cellular
functions include: Cell cycle: cyclin-dependent kinases (e.g., cdk4/6) and
cyclins (e.g., cyclin E). Cell metabolism: GLUT1, LDH-A, ASCT2 and SN2.
Protein synthesis: Initiation factors (eIF4E, eIF4G), elongation factors (EEF1B2).
Ribosome biogenesis: NPM, ribosomal RNA. Mitochondrial biogenesis:
PGC-1β, NRF-1. Apoptotic sensitization: ARF, BAX, BAK.
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Secondly, the new data from genome-wide studies of MYC’s
transcription factor function indicate that substantial fraction of
MYC regulated genes include regulators of cell metabolism, for
example “cell growth genes,” which mediate ribosome biogenesis
and protein synthesis, “energy metabolism genes” involved in
glycolysis, glutaminolysis and mitochondrial biogenesis as well
as “anabolic genes” including genes regulating the biosynthesis
of amino acids, nucleotides and lipids (Figure 1, see below).
Mitochondrial biogenesis increases bioenergetic capacity and
supports biosynthesis of cellular macromolecules needed for cell
proliferation and growth (Morrish and Hockenbery, 2014). MYC
activates key genes involved in the mitochondrial biogenesis
including PGC-1β and NRF-1 (Dang, 2013).
The new data does not change our principal view on MYC.
MYC is still a major driver of the cell cycle. However, it now
appears that MYC drives a very sustainable program of cell
proliferation by inducing sufficient production of biomass and
biosynthetic building blocks for cell growth, which ensures that
one cell division results in two about equal size of cells rather than
two small cells.
MYC–MASTER OF ANABOLIC PROCESSES
Anabolic Phenotype of Cancer Cells
Proliferating cancer cells have fundamentally different metabolic
status compared to differentiated, mainly resting adult cells;
measurable changes encompass all domains of cellular
metabolism, such as bioenergetics, biosynthesis and redox
potential (Cairns et al., 2011). Therefore, it is said that cells on a
path to cancer undergo “metabolic transformation” and in the
end of the path they develop a “cancer metabolic phenotype”
(DeBerardinis, 2008). The metabolic transformation of cancer
cells is often viewed as a general metabolic shift from energy
production to biosynthesis. Lipid metabolism provides an
illustrating example: While resting cells mainly oxidize lipids for
energy production, cancer cells or any growing and proliferating
cell types need to boost lipogenesis to satisfy the biomaterials
needs of growing cell membranes (Stine et al., 2015).
Even Warburg effect, the quintessential cancer metabolic
phenotype, can be seen as a specific adaptation to anabolic
metabolism. Warburg effect is the observation that cancer cells,
even in aerobic conditions, shift from oxidative phosphorylation
to glycolysis for ATP production (Warburg, 1956). However, the
glycolysis, which takes place in the cytosol, is relatively inefficient
way to produce bioenergy in comparison to mitochondrial
oxidative phosphorylation (glycolysis: 2 ATPs per glucose
molecule vs. 36 by mitochondrial oxidative phosphorylation)
(Vander Heiden et al., 2009). Therefore, the increased energy
need of growing cells for biomass production could not possibly
explain the Warburg effect. From the standpoint of anabolic
metabolism, glycolysis and the parallel running anabolic pentose
phosphate pathway (PPP) produce NADPH, which provides
the reducing equivalents for many biosynthetic reactions, such
as lipid synthesis and fatty acid elongation. Furthermore, the
first product of glycolysis, phosphorylated glucose (glucose-
6-phosphate), lies at starting point of both glycolysis and
pentose phosphate pathway, which produces in addition to
NADPH, ribose for the synthesis of nucleotides, and erythrose
4-phosphate (E4P) for the synthesis of aromatic amino acids
(Vander Heiden et al., 2009). Moreover, the end product of
glycolysis, pyruvate-derived acetyl-CoA, feeds lipid synthesis.
These examples illustrate that while the glycolytic oxidation of
glucose to pyruvate is an inefficient way to produce ATP, it still
produces plenty of reducing equivalents, free energy, and carbon
skeletons for biosynthesis (Vander Heiden et al., 2009).
MYC is inferred as a major player in metabolic transformation
of cancer cells due to its pervasive impact on the genes encoding
protein and enzyme mediators of glycolysis, glutaminolysis,
mitochondrial biogenesis, and biosynthesis of macromolecules
(Stine, Cairns, Kress). We single out below three metabolic
pathways, which are altered by MYC and which represent the
metabolic phenotype of many types of cancer cells (Figure 2).
Glycolysis
MYC enhances glucose uptake by upregulating glucose
transporters (GLUT1) (Osthus et al., 2000) and it
transcriptionally regulates virtually all glycolytic genes (Stine
et al., 2015 and references therein). In addition, MYC influences
pyruvate kinase mRNA splicing to favor expression of the
glycolysis-promoting PKM2 (embryonic pyruvate kinase)
isoform (David et al., 2010). In addition to promoting glycolysis,
MYC upregulates the expression of PPP genes, which action
increases partitioning of glucose carbon to PPP route at the
entrance of glycolysis pathway (Morrish et al., 2009; Wang et al.,
2011). Among the MYC’s glycolytic target genes, for example,
hexokinase 2 (HK2) and lactate dehydrogenase A (LDH-A)
genes use canonical E-boxes in their promoter regions to recruit
MYC (Kim et al., 2004). These genes likely represent the class
of regular metabolic targets of MYC, influenced already by low
levels of constitutive MYC expression in normally proliferating
cells (Figure 1). Recent evidence suggests that some of the MYC
influenced target genes with low affinity promoters for MYC
encode proteins involved in nutrient transport, glycolysis and
hypoxia responses (Lorenzin et al., 2016).
Thus, it is likely that a sub-set of MYC’s metabolic target
genes reside beyond the classical high-affinity E-box promoter
domain and therefore, comprise the group of genes that is only
affected by the supraphysiological MYC levels (Figure 1). The
projected benefit of increased anabolic metabolism for tumor
cells generates selection pressure toward supraphysiological
MYC expression but these metabolic transformation-specific
signaling circuits also create cancer vulnerabilities for therapeutic
intervention (discussed below, Lorenzin et al., 2016).
Glutaminolytic Programs
MYC has a notable role in regulation of glutamine metabolism,
and many recent findings elucidating the specific role of MYC
in glutaminolytic processes have stimulated broader interest
in glutamine as an essential nutrient for cancer cells. Glucose
and glutamine are both cells’ primary carbon sources for ATP
production and biosynthesis and these molecules are usually
available in high quantities since glutamine is the most abundant
circulating free amino acid in human blood (Mayers and Vander
Heiden, 2015). Glutamine is consumed in large quantities
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FIGURE 2 | MYC promotes anabolic metabolism. Normal quiescent cells (left) predominantly rely on mitochondrial oxidative phosphorylation (OXPHOS) to
generate ATP energy. Breakdown of glucose in glycolysis and mitochondrial Krebs cycle yields ATP and reducing equivalents (NADH and FADH2). The transfer of
electrons from reducing equivalents to molecular oxygen during OXPHOS completes the ATP-generating processes, yielding altogether 36 ATPs per glucose
molecule. Supraphysiological expression of MYC induces a shift to anabolic metabolism (right), which predominantly produces building blocks for biosynthesis of
macromolecules (nucleic acids, proteins, carbohydrates, lipids) at cost of less energy production. While aerobic glycolysis i.e. Warburg effect produces only 4 ATPs
per glucose molecule, the glycolysis and parallel running pentose phosphate pathway (not shown in the figure) generate plenty of reducing equivalents for biosynthetic
reactions. MYC also enhances utilization of glutamine-derived carbon for biosynthetic reactions and MYC transformed cells may use alpha-ketoglutarate (α-KG), a
product of glutaminolysis, as a key anaplerotic substrate to maintain Krebs cycle-dependent biosynthetic reactions. The metabolic target genes regulated by MYC are
marked with pink color. GLUT1, Glucose transporter 1; HK2, Hexokinase 2; LDH-A, Lactate dehydrogenase A; MCT, Monocarboxylate transporter; ASCT2, ASC
amino acid transporter; SN2, System N glutamine transporter 2; GLS1, Glutaminase 1.
in stressed and rapidly dividing cells (such as lymphocytes,
enterocytes of the small intestine and cancer cells) and used
for both bioenergy generation and as a source of carbon and
nitrogen for biosynthesis (Altman et al., 2016). MYC stimulates
glutamine uptake through regulation of glutamine transporters
(Wise et al., 2008). In the cytosol, glutamine can directly
contribute to nucleotide biosynthesis as an obligate nitrogen
donor (Lane and Fan, 2015). In the first step of glutaminolysis,
glutamine is converted to glutamate (glutamic acid) by action
of mitochondria-localized glutaminase (GLS1). MYC promotes
this step through transcriptional and posttranslational regulation
of GLS1 expression (Gao et al., 2009; Wise and Thompson,
2010; Haikala et al., 2016). Cytosolic glutamate is the primary
nitrogen donor for the synthesis of many non-essential amino
acids (serine, alanine, aspartate, and ornithine) (Gao et al.,
2009; Wise and Thompson, 2010). Glutamate is then further
metabolized to α-ketoglutarate (α-KG), which is one of the
intermediates of Krebs cycle (a.k.a tricarboxylic acid or TCA
or citric acid cycle) (Wise and Thompson, 2010). α-KG is
further oxidized in Krebs cycle to generate ATP and to
provide carbon skeletons for macromolecule synthesis (i.e.,
nucleotides, proteins and hexosamines) (DeBerardinis et al.,
2007; Wellen et al., 2010; Altman et al., 2016). Several
metabolic profiling studies, exploring the fate of glucose- or
glutamine-derived carbon in the cells’ metabolic processes,
have provided evidence that MYC-dependent glutaminolysis
stimulates and may indeed fuel Krebs cycle (DeBerardinis
et al., 2007; Le et al., 2012; Yuneva et al., 2012). For
example, under MYC’s influence and low glucose conditions,
the glutamine-derived carbons become enriched in the Krebs
cycle intermediates fumarate, malate and citrate (Le et al.,
2012). Therefore, under the influence of MYC, cells may
use glutamine as a key anaplerotic substrate to maintain
Krebs cycle-dependent biosynthetic reactions (see below). One
of the most striking features of MYC transformed cells is
their strict dependence of glutamine for survival (Wise et al.,
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2008). The glutamine-addiction of MYC transformed cells
provides possible therapeutic opportunities and for example,
pharmacologic inhibition of GLS1 has been shown to inhibit
tumor progression in mouse models of MYC-driven Burkitt’s
lymphoma or hepatocellular carcinoma (Le et al., 2012; Xiang
et al., 2015).
Glutamine Anaplerosis
Otto Warburg originally attributed poor utilization of the
mitochondrial oxidative phosphorylation by cancer cells to
mitochondrial damage. However, while glycolysis-derived
intermediates can importantly contribute to biosynthesis, they
cannot make up the whole pool of biosynthetic molecules
in the cell, which indicates a role for mitochondrial Krebs
cycle in anabolic reactions of the cancer cells (Ochoa-Ruiz
and Diaz-Ruiz, 2012). Indeed, emerging evidence suggest
both inter—and intratumor heterogeneity as well as metabolic
flexibility in the cancer cells’ exploitation of glycolysis vs. Krebs
cycle for energy production and biosynthesis (Ochoa-Ruiz
and Diaz-Ruiz, 2012). Krebs cycle not only produces ATP but
also number of metabolites for anabolic reactions. Typical
examples of Krebs cycle anabolic precursors include citrate that
is used for fatty acid synthesis or oxaloacetate that takes part
in gluconeogenesis, amino acid and lipid synthesis (Altman
et al., 2016). The enhanced eﬄux of Krebs cycle intermediates in
cancer cells for biosynthetic reactions is to some extent balanced
by accelerated glycolysis that boosts the influx of pyruvate to
Krebs cycle. However, it is believed that enhanced glycolysis is
not alone sufficient to compensate substantial eﬄux of Krebs
cycle intermediates to biosynthesis in rapidly growing and
proliferating cancer cells. The additional compensation comes
from anaplerotic reactions, which refill the Krebs cycle with
metabolites at the discrete steps where they are diverted away
from the cycle (eﬄux) for biosynthesis (Ochoa-Ruiz and Diaz-
Ruiz, 2012). For example, the glutamine -derived metabolite
α-ketoglutarate (α-KG) is part of Krebs flux, between isocitrate
and succinyl-CoA (Altman et al., 2016). The importance of
glutamine as an anaplerotic precursor has been long studied in
context of physiological responses of muscles or other organs to
exercise and starvation (Bowtell and Bruce, 2002; Owen et al.,
2002).
As discussed above, MYC’s effect on glutaminolysis can fuel
the Krebs cycle (Le et al., 2012). The importance of anaplerosis
for the metabolism of transformed cells has been addressed
for example in glioblastoma cells exhibiting aerobic glycolysis.
DeBerardinis et al. showed a rescue of glioblastoma cells from
glutamine deprivation-induce death with a cell permeable form
of α-KG, which cannot act as an amide donor in nucleotide
biosynthesis or as nitrogen source for the synthesis of non-
essential amino acids (DeBerardinis et al., 2007). Therefore,
the anaplerotic role of glutamine appears to be an important
factor in glutamine addiction of transformed cells. However, it
appears that MYC-induced diversion of glutamine to support cell
growth and proliferation requiresmore from glutamine than only
anaplerosis, since replacement of glutamine with α-ketoglutarate
(α-KG) in context of MYC-induced proliferation fails to rescue
the cell cycle progression (Wang et al., 2011). Nevertheless, α-
KG is sufficient to rescue cells from MYC-induced apoptosis in a
model that involves perturbation of RhoA-SRF-dependent GLS1
regulation (Haikala et al., 2016). Thus, it is tempting to speculate
that glutamine anaplerosis is critical for protection of cells
from MYC-dependent apoptosis whereas increased glutamine
utilization, which involves glutamine’s contribution to synthesis
of nucleotides and non-essential amino acids, is required for cell
proliferation and cell growth.
MYC AND AMPK–AT THE METABOLIC
AMBIVALENCE
Cell Viability Affairs: Consequences of
Declining ATP Levels
As discussed earlier, the necessity of incessantly proliferating
cells to shift their metabolic programs toward anabolic reactions
occurs at the expense of ATP production. However, an adequate
supply of ATP is necessary for normal cell functions and beneath
that adequacy cells will die. For example, even a transient drop
of cellular ATP levels in HeLa and other tumor cells is sufficient
to kill the cells by means of mitochondrial regulated apoptosis
(Vander Heiden et al., 1999; Izyumov et al., 2004). Since low ATP
level is both a signal of metabolic stress and a state that needs
rapid countering actions to restore energy, cells have evolved
specific mechanisms to monitor the AMP/ADP:ATP ratio in the
cells.
The principal cellular energy sensor is AMP activated kinase
(AMPK), which is composed of the catalytic α-subunit and two
regulatory subunits β and γ. AMPK has four adenine nucleotide-
binding clefts of which two (sites 1 and 3) bind AMP, ADP, or
ATP in a competative manner (Hardie, 2014; Zadra et al., 2015).
In unstressed or resting cells with high ATP:ADP, these sites are
predominantly occupied by ATP but under metabolic stress, the
increased levels of AMP and ADP in relation to ATP will lead
to progressive replacement of ATP with AMP or ADP in the
two AMPK’s responsive nucleotide-binding sites. AMPK activity
is further regulated via phosphorylation of Ser172 site, which
resides in the activation loop of kinase domain. The upstream
kinase that phosphorylates this regulatory phosphosite of AMPK
is LKB1 (liver kinase B1), which is a tumor suppressor mutated
or silenced in various sporadic cancers and in an inherited cancer
susceptibility syndrome, Peutz-Jeghers syndrome (Shaw et al.,
2004; Shackelford and Shaw, 2009; Hardie, 2015).
AMPK–Integrating Catabolic Processes to
Checkpoints of Cell Cycle and Death
AMPK activation coordinates number of metabolic signaling
pathways with the general purpose of switching on ATP
generating catabolic pathways, while simultaneously switching
off ATP consuming biosynthetic pathways. Some of these
pathways will be discussed in more detail below but the principal
impacts of AMPK activation on the catabolic pathways include
stimulation of glucose uptake, glycolysis, fatty acid uptake,
fatty acid oxidation, mitochondrial biogenesis and autophagy.
AMPK activates the main mitochondrial biogenesis inducer
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PGC-1α, which then activates sequence of events via NRF-1 and
NRF-2 transcription factors leading to increased production of
mitochondrial enzymes as well as transcription and replication
of mitochondrial DNA (Jornayvaz and Shulman, 2010). The
AMPK-mediated mitochondrial biogenesis has been implicated
in maintenance of energy homeostasis and cancer cell survival
(Chaube et al., 2015). The invariably AMPK-inhibited anabolic
pathways include inhibition of fatty acid synthesis, lipogenic
enzymes, triglyceride and cholesterol synthesis, transcription of
gluconeogenic enzymes, glycogen synthesis, protein synthesis
via mTOR, and ribosomal RNA synthesis. The AMPK-mediated
catabolic effects and associated target proteins are discussed here
only in the light of examples as AMPK pathways are thoroughly
covered in many recent excellent reviews (Mihaylova and Shaw,
2011; Hardie, 2014; Hardie et al., 2016).
The AMPK-induced ubiquitous negative impact on
anabolic metabolism suppresses cell growth and proliferation.
AMPK inhibits growth at least partly via AMPK-mediated
phosphorylation of TSC2 and raptor, which events inhibit
mTORC1 activity (Shackelford and Shaw, 2009). The inhibitory
effects of AMPK on cell proliferation additionally include for
example, suppression of BRAF and Hippo pathways mediator
YAP (Zadra et al., 2015 and references therein). AMPK has also
been considered as a mediator of metabolic G1/S checkpoint,
which is triggered by glucose deprivation. Lack of glucose
activates AMPK, which directly phosphorylates the N-terminal
Ser15 of p53, leading to initiation of p53-dependent cell-cycle
arrest or if the AMPK activity remains persistent, to cellular
senescence (Jones et al., 2005).
In addition to quiescence, metabolic activation of the AMPK-
p53 axis can have more grave consequences to the cells.
For example, glucose-deprivation induces AMPK and p53-
dependent cell death in thymocytes and in human bone
osteosarcoma U2OS cells (Okoshi et al., 2008). In this study, the
increased AMPK activity associated with p53 phosphorylation
at Ser46, which site has been previously implicated in apoptotic
function of p53 (Oda et al., 2000; Okoshi et al., 2008).
Furthermore, ATP depletion during neuronal excitotoxicity
(bioenergetic failure through glutamate receptor overactivation)
triggers activation of AMPK and if this activation is prolonged,
it will eventually lead to apoptosis through the action of pro-
apoptotic Bcl-2 family member BIM (Concannon et al., 2010).
In this system, the AMPK-induced cell death involves AMPK-
dependent inhibition of AKT kinase, which leads to two distinct
phosphorylation events that target the transcription factor
FOXO3, which is followed by FOXO3-induced upregulation of
BIM (Brunet et al., 1999; Davila et al., 2012). Sustained activation
of AMPK has also been linked to c-Jun N-terminal kinase (JNK)
and caspase-3-mediated apoptosis in liver cells (Meisse et al.,
2002).
MYC and Metabolic Stress-Induced Cell
Death Pathway: MYC Triggers
AMPK-Dependent Activation of P53
Given the opposing roles of MYC and AMPK pathways in
regulation of cell metabolism, it can be anticipated that cells with
both pathways simultaneously active will endure a significant
amount of stress with potentially dire consequences. Several
studies, including our own, have shown that an acute activation
of MYC induces or contributes to depletion of the cellular ATP
reservoirs and leads to concomitant activation of AMPK (Liu
et al., 2012; Nieminen et al., 2013). In these circumstances AMPK
strongly phosphorylates p53 at N-terminal serine 15, which
modification is known to liberate p53 from MDM2-dependent
inhibition and consequently, this leads to stabilization of p53
(Kruse and Gu, 2008).
However, from this point on, the nature of the p53 stabilizing
signal appears to influence the subcellular locale where p53
accumulates. In our study, we observed that while administration
of chemotherapeutic agents to mammary epithelial MCF10A
cells (without active MYC) led to nuclear accumulation of p53,
the activation of MYC in the same cells re-routed p53 to interact
with BAK and BCL-XL in the mitochondria. These events led to
conformational activation of BAK, which associates with higher
sensitivity of the cells to apoptosis (Nieminen et al., 2013).
These findings were consistent with earlier studies suggesting
a role for cytosolic p53 in direct physical regulation of the
mitochondrial BCL-2 family members (Green and Kroemer,
2009; Vaseva and Moll, 2009). Importantly, whilst MYC-
AMPK-p53 axis induced the N-terminal exposure of BAK, the
protein did not seem to dissociate from the inhibitory complex
with anti-apoptotic BCL-XL. These cells with conformationally
active BAK did not outright commit suicide by apoptosis
but were primed for death induction (Nieminen et al., 2007,
2013).
From these findings we formulated the hypothesis that
non-transformed cells have the ability to deal with declining
ATP levels because of AMPK-p53-mediated checkpoint control
mechanism (Jones et al., 2005). This metabolic checkpoint
mechanism arrests the cell cycle before the ATP levels drop
too low and thus, endows cells time to recover their ATP
reservoirs via catabolic pathways. On the contrary, the cancerous
cells with deregulated MYC expression will not be able to
downregulate MYC, nor exit from the cell cycle and nor switch
off the anabolic pathways. Therefore, these cells will continuously
cycle under low ATP levels and with active AMPK, leading
to progressive accumulation of p53 in the mitochondria and
gradually increasing sensitivity to apoptosis (Nieminen et al.,
2013). Such mechanism could have evolved to fulfill the role
of an intrinsic tumor suppressor mechanism, which limits the
proliferation of the cells with out-of-control cell cycle control
(Lowe et al., 2004).
Complex Relationship between MYC and
AMPK in Transformation and
Tumorigenesis
The findings discussed so far have highlighted AMPK as a
metabolic checkpoint protein and a potential tumor suppressor
protein, which claim is supported by large number of studies
exposing the anti-growth, anti-proliferative and anti-survival
actions of activated AMPK. However, it is now clear that the role
of AMPK in cancer is more complex and highly contextual (Liang
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andMills, 2013; Zadra et al., 2015). Nevertheless, the mechanistic
findings related to AMPK’s potential anti-cancer actions have
suggested that AMPK activating compounds, some of which have
been used for decades to treat metabolic disorders, could be
re-profiled for treatment of cancer (Fogarty and Hardie, 2010).
These therapeutic initiatives are substantiated by the findings
made over 10 years ago that patients with type 2 diabetes and
treated with metformin, which is an indirect activator of AMPK,
had significant lower risk of developing cancer than patients on
other medications (Evans et al., 2005; Bowker et al., 2006).
Specifically, the evidence for a tumor suppressor role of
AMPK in context of MYC expression comes from the studies
of Faubert et al, demonstrating that inactivation of the catalytic
α1-subunit of AMPK accelerates MYC-driven lymphomagenesis
(Faubert et al., 2013). In these experiments, depletion of AMPK
also favored aerobic glycolysis. For example, the AMPK-less
tumor cells showed increased glucose consumption, increased
lactate production and upregulation of transcription factor HIF-
1α and its glycolytic downstream targets (LDH-A, PDK1, and
ALDA). Furthermore, the tumors exhibited increased flux of
glucose carbons into lipids, indicating transition to anabolic
metabolism. Interestingly, the metabolic shift was reversed by
silencing of HIF-1α, suggesting that AMPK and HIF-1α have
opposing roles in the control of tumor metabolism.
Liver kinase B1 (LKB1) positively regulates the activity of at
least 14 AMPK related downstream kinases (AMPK and ARKs;
Katajisto et al., 2007), so no direct equivalence between loss
of LKB1 and loss of AMPK can be drawn but it is intriguing
to note that loss of LKB1 (and inferring from that, loss of
AMPK activity) dramatically promotes the oncogenic properties
of MYC in 3D culture system as well as MYC-dependent
tumorigenesis in mouse mammary gland (Partanen et al., 2007,
2012). Loss of LKB1 has also been shown to support growth-
promoting metabolism through mTORC1 hyperactivation and
reactive oxygen species-(ROS) dependent activation of HIF-1α
(Shackelford et al., 2009; Faubert et al., 2014).
Genetic mutations in AMPK are not frequent in human
cancer, although both point mutations and gene amplifications
have been observed (Liang and Mills, 2013). One study in breast
cancer has reported that AMPK is downregulated in majority
of examined cases and that reduced phospho-AMPK signal
correlates with breast cancer aggressiveness (Hadad et al., 2009).
Contrary to the suggested role of AMPK as a tumor
suppressor, there is also evidence that depletion of LKB1
or AMPK, and consequent loss of bioenergetic control,
hypersensitizes cells to apoptosis and renders cells resistant to
transformation (Shaw et al., 2004; Liang and Mills, 2013). In
context of MYC expression, Liu et al., demonstrated synthetic
lethal interaction between MYC and silencing of AMPK-related
kinase 5 (ARK5), which is upstream regulator of AMPK (Liu
et al., 2012). ARK5 was found to be essential for MYC-driven
expression of the mitochondrial respiratory chain proteins and
glutamine metabolism (Liu et al., 2012).
The current findings, which have provided support for both
tumor beneficial and pestilent AMPK functions, are perhaps
not contradictory if we consider the basal and high AMPK
activity as separate entities. We postulate that the basal level of
AMPK activity, which is important for bioenergetic homeostasis
of proliferation-active cells, is likely to be beneficial for tumor
growth at large whereas a high or prolonged catabolic AMPK
activity generates an imminent conflict with the expression
of oncogenes, such as MYC, which drive strongly anabolic
growth promoting pathways. The scenario, if true, would be
highly interesting from the therapeutic standpoint since AMPK
activating drugs could make the metabolic conflict worse and
promote selectively cell death in MYC transformed cells. Then, if
the tumor cells evolve to survive apoptosis through inactivation
of AMPK, this would lead to another type of apoptotic sensitivity
in escapee tumor cells due to lack of proper bioenergetic control
systems.
FUTURE PROSPECTS
MYC has been for decades one of the most intensively
studied oncoprotein, and while the protein itself is not
targetable by traditional pharmacological approaches, the
MYC-dependent pathways have formed a targetable domain
for variety of synthetic lethal approaches. To mention few
of recently identified plethora of MYC-dependent metabolic
vulnerabilities, MYC is synthetic lethal with losses engineered
to glucose metabolism genes, nucleotide metabolism genes,
glutamine/glutamate transporters, or to genes encoding
glycolysis or lipogenesis enzymes (reviewed in Stine et al., 2015).
In addition, pharmacological “tool compound” inhibitors of
LDH-A, GLS or lactate exporter MCT1 have been shown to
inhibit MYC-dependent tumorigenesis in mouse models of
cancer (Le et al., 2010, 2012; Wang et al., 2010; Doherty et al.,
2014).
However, the general problem with any type of signaling
intercepting strategy is that tumor cells quickly adapt to the
interception and evolve to use alternative signaling pathways
to restore the inhibited signaling capacity. The redundancy of
kinase pathways, rendering cells resistant to clinical EGFR-
tyrosine kinase inhibitors is a well-known example (Sun and
Bernards, 2014). Therefore, on one hand, it can be anticipated
that the broad repertoire of drugs for treatingmetabolic disorders
will facilitate new drug development and drug repositioning
initiatives aiming to exploit metabolic cancer vulnerabilities. On
the other hand, it is also a serious concern that the enormous
complexity and highly adaptive nature of metabolic networks will
provide many escape routes for metabolically targeted tumors,
which will eventually lead to therapy resistance.
We propose, not as a fact but as an incentive for future studies,
that the dual role of AMPK as an essential guardian of cellular
bioenergetic homeostasis and a formidable driver of catabolic
metabolism may set AMPK apart as a potentially non-redundant
cancer metabolic target. As discussed above, high or persistent
AMPK activity promotes induction of transient or permanent
cell cycle arrest or apoptosis. Therefore, AMPK activating
compounds, such as biguanides metformin and phenformin or
an allosteric activator A-769662 (Cool et al., 2006), could offer
pharmacological strategies to establish synthetic lethality with
MYC. Tumor cells could attempt escape from the synthetic
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FIGURE 3 | A model of metabolic stress and consequences caused by MYC-induced AMPK activity. MYC-induced metabolic transformation leads to
declined ATP levels and enhanced AMPK activity. AMPK activity predominantly stimulates catabolic reactions, generating conflicting signals with the MYC-induced
anabolic pathways (depicted in the figure, see text for details). The metabolic stress is directly or indirectly sensed by p53, which can contextually induce permanent
cell cycle arrest (senescence) or sensitize cells to apoptosis.
lethality with MYC by downregulating AMPK activity, which
event, however, would endanger tumor cells’ lives due to loss of
bioenergetic homeostasis.
Could tumor cells potentially evade AMPK’s anti-proliferative
or anti-survival functions by mutating p53? As discussed above,
both the glucose stress- and MYC-induced AMPK activity
induces p53 phosphorylation and stabilization, which promotes
cell cycle arrest, premature senescence or apoptosis (Jones et al.,
2005; Okoshi et al., 2008; Nieminen et al., 2013). Therefore,
it is clear that AMPK-p53 signaling axis is tightly coupled
to anti-proliferative or anti-survival AMPK functions. It is
also notable that metformin- or AICAR- (AMP analog that
stimulates AMPK activity)-induced cell cycle arrest in G1-
phase associates with increased phosphorylation of p53 at
Ser15 (Wonsey et al., 2002; Morrish et al., 2010; Priolo et al.,
2014). Nevertheless, the question about the requirement of
wild-type p53 specifically for AMPK’s pro-apoptotic and anti-
tumorigenic effects is unresolved. There is in vivo evidence
that metformin (or AICAR) exerts apoptotic effects in p53-
deficient, but not in the wild type p53 xenografts (Buzzai et al.,
2007). However, another study suggests that wild type p53 is
required for the antitumor effects of metformin (Li et al., 2015).
It is important to note that the missense mutated p53 proteins,
which are typically expressed in cancer, do have well-established
gain of function, transcription-independent and mitochondrial
apoptosis associated functions although the specific impacts of
missense mutations on the p53 function, including capacity to
mediate cell death, is debated (Vaseva and Moll, 2009; Freed-
Pastor and Prives, 2012). Therefore, the question about the
role of wild type and mutant p53 in mediating the metabolic
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stress and AMPK-dependent cell death warrants further
studies.
It is tempting to speculate that MYC-induced anabolic
reactions are highly incompatible with a persistently activated
catabolic AMPK function, creating an unresolvable metabolic
stress that exerts anti-proliferative or anti-survival effects
independently of p53 (Figure 3). For example, MYC-driven
tumor cells are highly dependent on ribosome biogenesis and
protein synthesis, requiring a collaboration between MYC and
mTOR signaling to satisfy the increased biosynthetic needs (van
Riggelen et al., 2010; Pourdehnad et al., 2013). Persistent AMPK
activity directly antagonizes mTOR-driven protein synthesis
(Bolster et al., 2002; Inoki et al., 2003; Dreyer et al., 2006) and such
catabolic program could create a synthetic lethal crisis in MYC
expressing cells. Earlier studies have suggested a highly context-
dependent role for mTOR in regulating apoptosis (Castedo et al.,
2002), and it remains for future studies to resolve how mixed
input signals to mTOR pathway might affect to cell viability.
Several reports have suggested that metformin and phenformin
downmodulate MYC levels in prostate and breast cancer cells
(Blandino et al., 2012 PMID: 22643892, Akinyeke et al., 2013).
This modulation has been suggested to occur via upregulation of
mir-33a, which targets MYC (Blandino et al., 2012). However, the
exact role of AMPK in this pathway has not been demonstrated.
One obvious scene of interest for future studies is the
antagonistic relationship of AMPK and MYC in anaplerosis
and how that will influence cell viability. Glutamine-deprivation
induced apoptosis of tumor cells and MYC-transformed cells
can be rescued by addition of exogenous alpha-ketoglutarate
(α-KG) to the cells, suggesting that the anaplerotic flux of
glutamine into the Krebs cycle is a critical survival mechanism
(DeBerardinis et al., 2007; Haikala et al., 2016). Besides the
Krebs cycle promoting function, glutamine anaplerosis and α-
KG have a role in protecting cells against reactive oxygen
species (ROS), constituting an additional glutamine related
pro-survival mechanism (Fedotcheva et al., 2006; Mailloux
et al., 2007; Niemiec et al., 2011). Indirect AMPK activator
metformin was recently shown to decrease the flow of glucose-
and glutamine-derived carbon into the Krebs cycle, leading to
reduced citrate production and lipid synthesis (Griss et al.,
2015). Such antagonizing effects of AMPK activity on glutamine
utilization could be selectively harmful for addicted tumor
cells and not such for normal cells. Further clarification of
the role of anaplerotic mechanisms as potential life-lines of
metabolically transformed tumor cells may not only new shed
light to intricacies of cancer cell metabolism but also pave way
for new effective cancer therapies.
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